Hidradenitis Suppurativa Market is Expected to Witness Robust Expansion at a Significant of 10.2% by 2032 | DelveInsight

January 19 20:44 2023
Hidradenitis Suppurativa Market is Expected to Witness Robust Expansion at a Significant of 10.2% by 2032 | DelveInsight
Hidradenitis Suppurativa Market

DelveInsight’s “Hidradenitis Suppurativa Market Insights” report includes a comprehensive understanding of current treatment practices, hidradenitis suppurativa emerging drugs, market share of individual therapies, and historical, current as well as forecasted hidradenitis suppurativa market size from 2019 to 2032, segmented into the 7MM [the United States, the EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan].


Key Takeaways from the Hidradenitis Suppurativa Market Report

  • As per DelveInsight analysis, the hidradenitis suppurativa market size in the 7MM was approximately USD 1,150 in 2021.
  • According to the assessment done by DelveInsight, the estimated total hidradenitis suppurativa diagnosed prevalent population in the 7MM was approximately 1.2 million in 2021.
  • Leading hidradenitis suppurativa companies such as InflaRx, Novartis, UCB, ChemoCentryx, Eli Lilly and Company, Janssen Biotech, AbbVie, Pfizer, Amgen, Incyte Corporation, CSL Behring, Kymera Therapeutics, Aclaris Therapeutics, Boehringer Ingelheim, Azora Therapeutics, and others are developing novel hidradenitis suppurativa drugs that can be available in the hidradenitis suppurativa market in the upcoming years.
  • The hidradenitis suppurativa therapies in the pipeline include IFX-1, Cosentyx /Secukinumab, Avacopan, Bimekizumab, Bermekimab, Zunsemetinib (ATI-450), and others.
  • The hidradenitis suppurativa market size is expected to increase owing to the increase in the prevalent population of hidradenitis suppurativa patients in the 7MM. 
  • In December 2022, Kymera announced positive results from Phase 1 clinical trials evaluating KT-474 in patients suffering from hidradenitis suppurativa and atopic dermatitis, after which Sanofi decided to advance KT-474 into Phase 2 clinical trials for which IND is cleared by the US FDA. 
  • In December 2022, UCB reported positive data from the BE HEARD I and BE HEARD II Phase 3 clinical trials of bimekizumab in moderate to severe hidradenitis suppurativa adult patients. 
  • In September 2022, abstract findings at the 31st European Academy of Dermatology and Venereology (EADV) Congress showed that Novartis’ Cosentyx (secukinumab) Showed Rapid, Sustained Improvement of Hidradenitis Suppurativa. 
  • In September 2022, JAK1-selective inhibitor povorcitinib showed dosage-dependant efficacy for the treatment of hidradenitis suppurativa in a randomized, placebo-controlled, Phase 2 study—presented at the European Academy of Dermatology and Venerology (EADV) 2022 Congress.
  • In August 2022, Aristea Therapeutics (Aristea), a clinical-stage immunology-focused drug development company advancing novel therapies to treat serious inflammatory diseases, announced the dosing of the first patient in its Phase 2a trial evaluating RIST4721, a CXCR2 antagonist, for the treatment of hidradenitis suppurativa.


Discover which therapies are expected to grab major hidradenitis suppurativa market share @ Hidradenitis Suppurativa Market Report


Hidradenitis Suppurativa Overview

Hidradenitis suppurativa is a complex dermatological disease characterized by recurrent painful nodules and suppuration in areas such as the axilla and groin. It is also known as Acne inversa and there is no biological or pathological test to facilitate diagnosis; its clinical features and chronicity can define it.

The exact cause of hidradenitis suppurativa is unclear, but the condition probably results from a combination of genetic and environmental factors. Lumps develop as a result of blocked hair follicles. It is more common in women than men, and in obese and smokers, hidradenitis suppurativa is likely to worsen the symptoms

The symptoms of hidradenitis suppurativa range from mild to severe. It causes a mixture of boil-like lumps, blackheads, cysts, scarring, and channels in the skin that leak pus. Scoring systems for the assessment of hidradenitis suppurativa severity include Hurley staging, Physician’s Global Assessment (PGA), the modified Sartorius score (MSS), and the hidradenitis suppurativa severity index (HSSI).

Systemic therapies, mainly antibiotics and retinoids, are the treatment’s mainstay. Topical therapies are mainly used in cases of mild to moderate disease conditions. Adalimumab (Humira) is the only approved drug for treating moderate to severe hidradenitis suppurativa.


Hidradenitis Suppurativa Epidemiology Segmentation

DelveInsight estimates that there were approximately 1.2 million hidradenitis suppurativa diagnosed prevalent cases in the 7MM in 2021. Among the EU5 countries, Germany had the highest number of hidradenitis suppurativa diagnosed prevalent cases in 2021.

The hidradenitis suppurativa market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into

  • Total Prevalent Pool
  • Diagnosed Pool
  • Gender-specific Prevalent Pool
  • Age-specific Prevalent Pool
  • Stage-specific Prevalent Pool 
  • Treated Moderate to Severe Prevalent Pool


Download the report to understand which factors are driving hidradenitis suppurativa epidemiology trends @ Hidradenitis Suppurativa Epidemiological Insights


Hidradenitis Suppurativa Treatment Market 

The treatment management usually requires a combination of lifestyle changes, medical therapy, laser or surgical intervention and considerable psychological support. Several pharmacological treatment options include topical and systemic antibiotics, corticosteroids, anti-androgen therapy, systemic retinoids, and immunosuppressive agents, including biologics. 

In a small study, Metformin has been used to treat metabolic syndrome associated with hidradenitis suppurativa and has been reported to reduce hidradenitis suppurativa disease activity effectively. Laser hair removal with a 1,064nm  laser has shown promise, but many patients cannot afford this treatment due to limited insurance coverage. Humira (Abbvie) is the first and only approved drug for Moderate to Severe hidradenitis suppurativa. In September 2015, the US Food and Drug Administration (FDA) approved Humira to treat moderate to severe hidradenitis suppurativa. 

The approval of Humira is a critical milestone in the lives of people with hidradenitis suppurativa who, up until this point, had no approved treatments. The product was approved by the European Commission (EC), in July 2015, for the treatment of active moderate to severe hidradenitis suppurativa in adults with an inadequate response to conventional systemic hidradenitis suppurativa treatment.

Humira was designated for the indication of hidradenitis suppurativa as an orphan drug in 2017 and was approved for the indication of hidradenitis suppurativa for the first time in Japan in February 2019. Humira is actually the only drug in Japan for hidradenitis suppurativa indication. 

Even though hidradenitis suppurativa is affecting the lives of millions of people worldwide, there are not many treatment options to treat the underlying cause, nor has there been an improvement in therapeutic options in the last several decades. With only one approved drug in the market, i.e., Humira, there is a high need for alternative therapies due to serious adverse events associated with Adalimumab, including injection site serious infections.


To know more about hidradenitis suppurativa treatment, visit @ Hidradenitis Suppurativa Treatment Guidelines


Hidradenitis Suppurativa Pipeline Therapies and Key Companies

  • IFX-1: InflaRx 
  • Cosentyx/Secukinumab: Novartis
  • Avacopan: ChemoCentryx
  • Bermekimab: Janssen Pharmaceutical/XBiotech
  • Zunsemetinib (ATI-450): Aclaris Therapeutics


Learn more about the hidradenitis suppurativa therapies in clinical trials @ Drugs for Hidradenitis Suppurativa Treatment 


Hidradenitis Suppurativa Market Dynamics

Hidradenitis suppurativa market is currently having vast pipeline therapies targeting interleukins, including (i.e., IL-17, IL-1), anti-TNF, JAKi, and anti-complement factor. The upcoming therapies of hidradenitis suppurativa are expected to come with a patient-convenient Route of administration and are also expected to increase the treatment duration. 

In the current treatment market, only HUMIRA is approved for the treatment of moderate to severe hidradenitis suppurativa with modest efficacy and, therefore, provides potentially lucrative market opportunities. No treatment options are available in relapsed/ refractory patients to HUMIRA. However, off-label therapies like antibiotics and retinoids are still the treatment backbone of hidradenitis suppurativa. There are no definite biomarkers available for the early and progressive forms of the disease. 

The expected entry of biosimilars of HUMIRA from 2023 in the US will erode the market sales of HUMIRA. Moreover, the market value of HUMIRA in Europe has already started declining from 2018, and sales value decline is expected to be much faster in future years due to multiple launches of biosimilars in 2019 and as well as in upcoming years.



Scope of the Hidradenitis Suppurativa Market Report

  • Therapeutic Assessment: Hidradenitis suppurativa current marketed and emerging therapies
  • Hidradenitis Suppurativa Market Dynamics: Hidradenitis suppurativa market drivers and barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Unmet Needs, KOL’s views, Analyst’s views, Hidradenitis Suppurativa Market Access and Reimbursement


Discover more about drugs for hidradenitis suppurativa in development @Hidradenitis Suppurativa Clinical Trials


Table of Contents


Hidradenitis Suppurativa Market Key Insights


Hidradenitis Suppurativa Market Report Introduction


Hidradenitis Suppurativa Market Overview at a Glance


Hidradenitis Suppurativa Market Executive Summary


Hidradenitis Suppurativa Key Events


Epidemiology and Market Methodology


Disease Background and Overview


Hidradenitis Suppurativa Treatment and Management


Hidradenitis Suppurativa Epidemiology and Patient Population


Key Finding


Assumptions and Rationale


Total Prevalent Population of Hidradenitis Suppurativa in the 7MM


United States






Patient Journey


Key Endpoints in Hidradenitis Suppurativa Clinical Trials


Hidradenitis Suppurativa Marketed Drugs


Hidradenitis Suppurativa Emerging Drugs


Seven Major Hidradenitis Suppurativa Market Analysis


Key Finding


Market Outlook


Attribute Analysis


Key Market Forecast Assumptions


Total Market Size of Hidradenitis Suppurativa in the 7MM


United States






Unmet Needs


SWOT Analysis


Market Access and Reimbursement




DelveInsight Capabilities




About DelveInsight


About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting